Literature DB >> 10704010

Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography.

G W Peng1, R P Stryd, S Murata, M Igarashi, K Chiba, H Aoyama, M Aoyama, T Zenki, N Ozawa.   

Abstract

An HPLC-UV method was developed for assay of linezolid in dog, rat, mouse, and rabbit plasma. Linezolid and the internal standard were extracted on a solid phase cartridge (SPE) and separated on a reversed-phase column (C8, 4.6x150 mm, 5 microm) with 20% acetonitrile in water as mobile phase. The SPE quantitatively recovered linezolid and the internal standard from plasma samples. The chromatographic peak height ratio or peak area ratio based on UV absorbency at 251 nm was used for quantitative analysis. The assay procedures were simple and the assay was specific and had adequate precision and accuracy. Calibration standards with concentrations over the range of 0.01 20 microg/ml were validated for routine sample analysis to support the pharmacokinetic and toxicology studies with linezolid in dog, rat, mouse, and rabbit. Analysis of quality control samples showed the coefficients of variation were usually <10% and the measured and theoretical concentrations differed by <10% in most assays. Linezolid in the plasma samples was stable when stored at below -20 degrees C for at least 63 days, at room temperature (22-23 degrees C) for up to 24 h, and after three freeze-thaw cycles. This HPLC method has been successfully used in multiple laboratories to assay plasma samples from pharmacokinetic and toxicology studies with linezolid in the animal species.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10704010     DOI: 10.1016/s0731-7085(98)00310-0

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  21 in total

1.  Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections.

Authors:  P Villani; M B Regazzi; F Marubbi; P Viale; L Pagani; F Cristini; B Cadeo; G Carosi; R Bergomi
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis.

Authors:  George Athanassopoulos; Angelos Pefanis; Vissaria Sakka; Dimitrios Iliopoulos; Despina Perrea; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.

Authors:  Piergiorgio Cojutti; Manjunath P Pai; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

5.  Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.

Authors:  Ryan L Crass; Pier Giorgio Cojutti; Manjunath P Pai; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 6.  Pharmacological issues of linezolid: an updated critical review.

Authors:  Antonello Di Paolo; Paolo Malacarne; Emanuele Guidotti; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

7.  In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus.

Authors:  Cedric Jacqueline; Jocelyne Caillon; Olivier Grossi; Virginie Le Mabecque; Anne-Françoise Miegeville; Denis Bugnon; Eric Batard; Gilles Potel
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

8.  Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection.

Authors:  Katsunori Yanagihara; Yukihiro Kaneko; Toyomitsu Sawai; Yoshitsugu Miyazaki; Kazuhiro Tsukamoto; Yoichi Hirakata; Kazunori Tomono; Jun-Ichi Kadota; Takayoshi Tashiro; Ikuo Murata; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Determination of Residual Solvents in Linezolid by Static Headspace GC.

Authors:  Xiao-Zhen Feng; Guo-Cheng Han; Jianhe Qin; Shi-Min Yin; Zhencheng Chen
Journal:  J Chromatogr Sci       Date:  2015-12-10       Impact factor: 1.618

10.  Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion.

Authors:  Maria Saroglou; Stavros Tryfon; Georgios Ismailos; Ioannis Liapakis; Manolis Tzatzarakis; Aristidis Tsatsakis; Apostolos Papalois; Demosthenes Bouros
Journal:  J Inflamm (Lond)       Date:  2010-05-18       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.